{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ROBERT CYRAN", "person": [{"firstname": "Robert", "rank": 1, "lastname": "CYRAN", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "376", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Pfizer Inc", "is_major": "N", "name": "organizations"}, {"rank": "3", "value": "Medivation Inc", "is_major": "N", "name": "organizations"}, {"rank": "4", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Astellas Pharma", "is_major": "N", "name": "organizations"}], "lead_paragraph": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying.", "pub_date": "2016-08-23T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying....", "multimedia": [], "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html", "slideshow_credits": null, "blog": [], "_id": "57bb5b0295d0e021d798203d", "headline": {"main": "The Flaws in Pfizer\u2019s Plan to Acquire Medivation", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}